Data compiled by Redley Lamar · ChainSifter Intelligence
2Suppliers
7Customers
3Debt Items
20Related Chains
Source-Backed Evidence Depth
Quanterix Corporation (QTRX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
13Total relationships
3Distinct source URLs
7High confidence
0.808Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Reciprocal relationship from LLY graph: Reciprocal relationship from QTRX graph: accounted for greater than % of the Company’s total revenue. For the year ended December 31, 2023, customer of approxi…
accounted for greater than % of the Company’s total revenue. For the year ended December 31, 2023, customer of approximately $ million revenue accounted for greater than % of the Company’s total reve…
Quanterix Corporation Customers
Ticker
Name
Confidence
Evidence
USGOV-DEPARTMENT-OF-HEALTH-AND-HUMAN-SERVICES
USGOV-DEPARTMENT-OF-HEALTH-AND-HUMAN-SERVICES
95%
USAspending awards from Department of Health and Human Services: $209,164 across 5 awards. 75N93021P00634 QUANTERIX SP-X ULTRA-SENSITIVE BIOMARKER DETECTION SYSTEM; 75N95024P00082 MAINTENANCE SERVICE…
SIMOA
SIMOA
92%
All of the Company's collaboration and license revenue was generated by Simoa technology.
SPATIAL-BIOLOGY
SPATIAL-BIOLOGY
92%
All of the Company's collaboration and license revenue was generated by Simoa technology.
Reciprocal relationship from LLY graph: Reciprocal relationship from QTRX graph: Reciprocal relationship from LLY graph: Reciprocal relationship from QTRX graph: Reciprocal relationship from LLY grap…
nary shares of UltraDx with a deemed fair value of $ million. The issuance of the shares was contingent on UltraDx completing a preferred share financing under the terms and conditions in the UltraDx…
AKOYA-BIOSCIENCES-INC
AKOYA-BIOSCIENCES-INC
62%
therapies and diagnostics and has the potential to identify early-stage disease markers before symptoms appear. Our instruments are designed to be used either with assays fully developed by us, inclu…